Liraglutide Versus Exenatide Once Weekly: Persistence, Adherence, and Early Discontinuation.

Yu M, Xie J, Fernandez Lando L, Kabul S, Swindle RW

Clinical therapeutics17 Dec 2015Cited by 29 (Europe PMC)

PMID26706658DOI10.1016/j.clinthera.2015.11.017PepBankPUB-26706658

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

4 results from studies that gave the peptide. 4 results from people.

01HumanObservational studyOther
In propensity-matched US adults with type 2 diabetes, 66% persisted with daily liraglutide compared with 63% with once-weekly exenatide over 6 months.
In plain wordsIn US adults with type 2 diabetes, 66% stayed on daily liraglutide for 6 months compared with 63% on once-weekly exenatide.
Peptide
Liraglutide
Outcome
Not applicablePersistence over 182 days
Study
n = 12,306
Comparator
Exenatide once weekly
Outcome group
Treatment adherence and retention · Whole body
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Persistence
66%
liraglutide
Persistence
63%
exenatide QW
Source sentences
Summary
The overall persistence observed with liraglutide was 66% compared with 63% for exenatide QW.
1 context sentence(design, population, supporting numbers)
Summary · context
This retrospective observational study used U.S. insurance claims data to compare persistence and adherence to GLP-1 receptor agonists in patients with T2D initiating once weekly (QW) exenatide or daily liraglutide over a 6-month follow-up period.
Report a problemFND-2670665801
02HumanObservational studyOther
In propensity-matched US adults with type 2 diabetes, mean adherence (PDC) was 0.689 for liraglutide and 0.694 for once-weekly exenatide over 6 months.
In plain wordsIn US adults with type 2 diabetes, adherence over 6 months was about the same for daily liraglutide and once-weekly exenatide.
Peptide
Liraglutide
Outcome
Not applicableMean proportion of days covered (PDC)
Study
n = 12,306
Comparator
Exenatide once weekly
Outcome group
Treatment adherence and retention · Whole body
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Mean PDC
0.689 proportion
liraglutide
Mean PDC
0.694 proportion
exenatide QW
Source sentences
Summary
The mean (SD) PDC adherence during the 6-month follow-up period was 0.694 (0.309) for the exenatide QW cohort and 0.689 (0.286) for the liraglutide cohort.
1 context sentence(design, population, supporting numbers)
Summary · context
This retrospective observational study used U.S. insurance claims data to compare persistence and adherence to GLP-1 receptor agonists in patients with T2D initiating once weekly (QW) exenatide or daily liraglutide over a 6-month follow-up period.
Report a problemFND-2670665802
03HumanObservational studyOther
In propensity-matched US adults with type 2 diabetes, 47% of liraglutide patients and 51% of once-weekly exenatide patients reached a PDC of 0.8 or more.
In plain wordsIn US adults with type 2 diabetes, 47% on daily liraglutide and 51% on once-weekly exenatide reached the high adherence threshold.
Peptide
Liraglutide
Outcome
Not applicablePatients with PDC of 0.8 or more
Study
n = 12,306
Comparator
Exenatide once weekly
Outcome group
Treatment adherence and retention · Whole body
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Patients with PDC >=0.8
5820 patients
liraglutide
Patients with PDC >=0.8
47%
liraglutide
Patients with PDC >=0.8
6309 patients
exenatide QW
Patients with PDC >=0.8
51%
exenatide QW
Source sentences
Summary
The PDC threshold of ≥0.8 during the 6-month follow-up period was met by 6309 (51%) and 5820 (47%) patients in the exenatide QW and liraglutide cohorts, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
This retrospective observational study used U.S. insurance claims data to compare persistence and adherence to GLP-1 receptor agonists in patients with T2D initiating once weekly (QW) exenatide or daily liraglutide over a 6-month follow-up period.
Report a problemFND-2670665803
04HumanObservational studyOther
In US adults with type 2 diabetes on liraglutide, 77% of those previously treated with twice-daily exenatide continued treatment versus 63% of those not previously treated with it.
In plain wordsIn US adults on liraglutide, more who had used twice-daily exenatide before stayed on treatment (77%) than those who had not (63%).
Peptide
Liraglutide
Outcome
Not applicablePersistence by previous exenatide BID treatment
Study
n: not reported in source
Comparator
Liraglutide patients not previously treated with exenatide BID
Outcome group
Treatment adherence and retention · Whole body
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Continued treatment, previous exenatide BID
77%
liraglutide
Continued treatment, no previous exenatide BID
63%
liraglutide
Source sentences
Summary
For the liraglutide cohort, 77% of previous exenatide BID patients continued treatment versus 63% of patients who were not previously treated with exenatide BID.
1 context sentence(design, population, supporting numbers)
Summary · context
This retrospective observational study used U.S. insurance claims data to compare persistence and adherence to GLP-1 receptor agonists in patients with T2D initiating once weekly (QW) exenatide or daily liraglutide over a 6-month follow-up period.
Report a problemFND-2670665804

Studies that did not test the peptide alone5

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

05HumanNot a test of Exenatide (exendin-4) aloneObservational studyOther
In matched type 2 diabetes cohorts, persistence was 63% with weekly exenatide versus 66% with liraglutide.
In plain wordsIn matched type 2 diabetes cohorts, weekly exenatide was linked to lower persistence than liraglutide.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseTreatment persistence
Study
n = 24,612
Comparator
Daily liraglutide
Outcome group
Treatment adherence and retention · Whole body
Measurements
Persistence
63%
exenatide QW
Persistence
66%
liraglutide
Source sentences
Summary
The overall persistence observed with liraglutide was 66% compared with 63% for exenatide QW.
3 context sentences(design, population, supporting numbers)
Summary · context
Each matched cohort included 12,306 patients.
Summary · context
This retrospective observational study used U.S. insurance claims data to compare persistence and adherence to GLP-1 receptor agonists in patients with T2D initiating once weekly (QW) exenatide or daily liraglutide over a 6-month follow-up period.
Summary · context
A 1:1 propensity score match was used to account for selection bias.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2670665805
06HumanNot a test of Exenatide (exendin-4) aloneObservational studyOther
In matched type 2 diabetes cohorts, mean adherence was 0.694 with weekly exenatide versus 0.689 with liraglutide.
In plain wordsIn matched type 2 diabetes cohorts, weekly exenatide was linked to slightly higher mean adherence than liraglutide.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseMean proportion of days covered
Study
n = 24,612
Comparator
Daily liraglutide
Outcome group
Treatment adherence and retention · Whole body
Measurements
Mean proportion of days covered
0.694 proportion
exenatide QW
Mean proportion of days covered
0.689 proportion
liraglutide
Source sentences
Summary
The mean (SD) PDC adherence during the 6-month follow-up period was 0.694 (0.309) for the exenatide QW cohort and 0.689 (0.286) for the liraglutide cohort.
3 context sentences(design, population, supporting numbers)
Summary · context
Each matched cohort included 12,306 patients.
Summary · context
This retrospective observational study used U.S. insurance claims data to compare persistence and adherence to GLP-1 receptor agonists in patients with T2D initiating once weekly (QW) exenatide or daily liraglutide over a 6-month follow-up period.
Summary · context
A 1:1 propensity score match was used to account for selection bias.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2670665806
07HumanNot a test of Exenatide (exendin-4) aloneObservational studyOther
In matched type 2 diabetes cohorts, 51% with weekly exenatide versus 47% with liraglutide reached the adherence threshold.
In plain wordsIn matched type 2 diabetes cohorts, weekly exenatide was linked to more patients reaching the adherence threshold than liraglutide.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseProportion of days covered at least 0.8
Study
n = 24,612
Comparator
Daily liraglutide
Outcome group
Treatment adherence and retention · Whole body
Measurements
Patients with PDC ≥0.8
6309 patients
exenatide QW
Patients with PDC ≥0.8
51%
exenatide QW
Patients with PDC ≥0.8
5820 patients
liraglutide
Patients with PDC ≥0.8
47%
liraglutide
Source sentences
Summary
The PDC threshold of ≥0.8 during the 6-month follow-up period was met by 6309 (51%) and 5820 (47%) patients in the exenatide QW and liraglutide cohorts, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
Each matched cohort included 12,306 patients.
Summary · context
This retrospective observational study used U.S. insurance claims data to compare persistence and adherence to GLP-1 receptor agonists in patients with T2D initiating once weekly (QW) exenatide or daily liraglutide over a 6-month follow-up period.
Summary · context
A 1:1 propensity score match was used to account for selection bias.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2670665807
08HumanNot a test of Exenatide (exendin-4) aloneObservational studyOther
Among weekly exenatide recipients, persistence was 76% with previous twice-daily exenatide use versus 59% without previous use.
In plain wordsAmong weekly exenatide recipients, previous twice-daily exenatide use was linked to higher persistence than no previous use.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseWeekly exenatide persistence by previous exenatide use
Study
n: not reported in source
Comparator
No previous twice-daily exenatide
Outcome group
Treatment adherence and retention · Whole body
Measurements
Persistence, exenatide QW cohort
76%
previous exenatide BID
Persistence, exenatide QW cohort
59%
no previous exenatide BID
Source sentences
Summary
For the exenatide QW cohort, 76% of patients treated previously with BID exenatide continued treatment in the 6-month follow-up period compared with 59% who were not previously treated with exenatide BID.
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective observational study used U.S. insurance claims data to compare persistence and adherence to GLP-1 receptor agonists in patients with T2D initiating once weekly (QW) exenatide or daily liraglutide over a 6-month follow-up period.
Summary · context
A 1:1 propensity score match was used to account for selection bias.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2670665808
09HumanNot a test of Exenatide (exendin-4) aloneObservational studyOther
Among liraglutide recipients, persistence was 77% with previous twice-daily exenatide use versus 63% without previous use.
In plain wordsAmong liraglutide recipients, previous twice-daily exenatide use was linked to higher persistence than no previous use.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseLiraglutide persistence by previous exenatide use
Study
n: not reported in source
Comparator
No previous twice-daily exenatide
Outcome group
Treatment adherence and retention · Whole body
Measurements
Persistence, liraglutide cohort
77%
previous exenatide BID
Persistence, liraglutide cohort
63%
no previous exenatide BID
Source sentences
Summary
For the liraglutide cohort, 77% of previous exenatide BID patients continued treatment versus 63% of patients who were not previously treated with exenatide BID.
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective observational study used U.S. insurance claims data to compare persistence and adherence to GLP-1 receptor agonists in patients with T2D initiating once weekly (QW) exenatide or daily liraglutide over a 6-month follow-up period.
Summary · context
A 1:1 propensity score match was used to account for selection bias.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2670665809

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 4 to 8Current
28 Oct 2026, 02:03 UTC
The same notice was added 5 times, first on 22 Oct 2026, 02:26 UTC. The status did not change between them.
Study results updated
Version 3
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 2
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.